Since joining Benchmark in 2018, according to a statement released by the aquaculture genetics, health and nutrition business, Raeber has “played an instrumental role in the execution of the company’s new strategy, leading the review and streamlining of the product pipeline, the integration of Benchmark’s innovation teams and the reorganisation of the group’s in-house trial facilities”.
Having completed these projects, as the company moves from an R&D investment phase into commercial execution, Raeber has decided that this is the right time to pursue new challenges.
The news comes on the same day company has announced that Philippe Léger has decided to retire from his current position as interim CEO of Benchmark on 1 July. Léger started his career in 1979 at the University of Ghent as a research scientist, before joining the spin-off company that became INVE, now Benchmark’s advanced nutrition division. Léger led advanced nutrition until he turned 65, handing over his position to Athene Blakeman in July 2019. Following the resignation of Malcolm Pye as Benchmark’s CEO in 2019, Léger agreed to extend his service leading the executive management team and supporting Peter George, executive chairman. Having completed the handover in advanced nutrition and following the appointment of incoming CEO, Trond Williksen from 1 June 2020, Philippe has decided it is the right time to pursue new projects.
George commented: “On behalf of the board I would like to thank Alex and Philippe for their important contributions to Benchmark, particularly the roles they have played in the new strategy and restructuring we initiated in 2019. We wish them success in their future endeavours.”